STAT: Only about 100 people have gotten Aduhelm since approval

[anonymous]

Three months into the launch of the Alzheimer’s disease treatment Aduhelm, only about 100 patients have received a dose of Biogen’s drug, STAT has learned.

According to a person familiar with the matter, the early days of Aduhelm’s launch have fallen far short of internal projections, and the company’s progress is drastically below Wall Street’s expectation that thousands of patients would be using the drug by now. Due to Aduhelm’s slow uptake and the concern that Biogen won’t meet its revenue targets, company executives are now considering a reduction in spending, which could include layoffs, the person said.

In a statement, Biogen did not comment on the number of patients who have received Aduhelm or on the potential for cost-cutting and layoffs. The company continues “to see a high level of patient interest, and we are making steady progress” on making Aduhelm widely available, a spokesperson said.

Read more.

 

[anonymous]

Shitshow...

 

[anonymous]

Aduhelm is in more trouble

If it wasn’t clear just how controversial the Aduhelmapproval was, a DC-based medical center made it obvious by reportedly banning all Biogen representatives from its seven offices. In a photo circulating on Twitter, The Neurology Center alluded to the growing controversy over the Alzheimer’s drug and said Biogen reps are “no longer welcome.” The company is already struggling to get the treatment off the ground, and concerns only heightened when analysts unearthed new safety data suggesting a troubling recurrence of ARIA in the small group of early commercial patients who have been dosed.

 

[anonymous]

Alzheimer's drug Aduhelm: What one ex-FDA adviser called 'probably the worst drug approval decision in recent US history' - CNNPolitics

Alzheimer's drug Aduhelm: What one ex-FDA adviser called 'probably the worst drug approval decision in recent US history' - CNNPolitics

 

[anonymous]

Tim Anderson on Twitter: "Why is this so important? - Adverse events, vascular edema & hemorrhage, were higher among pts receiving #aducanumab -Risk of these events are likely even higher in trial ineligible groups, esp those on anticoag/antiplatelets, prior stroke/CVD = most pts with dementia" / Twitter

https://twitter.com/timandersonmd/status/1436031877522018304

 

[anonymous]

"Mass General Brigham has decided that it will not provide aducanumab (Aduhelm™) for the treatment of Alzheimer’s disease at this time. Like all other drugs used within Mass General Brigham, aducanumab was subject to evaluation by the Mass General Brigham Pharmacy and Therapeutics Committee, a multidisciplinary panel of experts from across the academic health system, that serves as decision-making body to Mass General Brigham on formulary management. The evaluation included a thorough review of clinical, economic, and operational considerations. This decision was based on the current data regarding aducanumab’s safety and efficacy. We understand that this may be difficult news for some of our patients. However, we fully support continued evaluation of this medication and should new data become available we will re-evaluate this decision"